FDA List Serve ~ Important Information About Sustiva (efavirenz) and Pregnancy

ROCKVILLE, Md., March 31, 2005--Bristol-Myers Squibb Company has issued a
Dear Health Care Provider Letter highlighting important information about Sustiva and pregnancy.

The contents of the letter are reproduced below.

March 2005

Re: Important Change in SUSTIVA (efavirenz) Package Insert —
Change from Pregnancy Category C to D

Dear Health Care Provider,
Bristol-Myers Squibb Company would like to make clinicians who are caring for HIV-1-infected patients
aware of important new information in the SUSTIVA Package Insert regarding pregnancy. The pregnancy
category for SUSTIVA has been changed from Category C (Risk of Fetal Harm Cannot Be Ruled Out) to
Category D (Positive Evidence of Fetal Risk). This change is a result of four retrospective reports
of neural tube defects in infants born to women with first trimester exposure to SUSTIVA including
three cases of meningomyelocele and one Dandy Walker Syndrome. As SUSTIVA may cause fetal
harm when administered during the first trimester to a pregnant woman, pregnancy should be
avoided in women receiving SUSTIVA.

Women of childbearing potential should undergo pregnancy testing before initiation of SUSTIVA.
If SUSTIVA is used during the first trimester of pregnancy, or if the patient becomes pregnant
while taking this drug, the patient should be apprised of the potential harm to the fetus.
Though there are no adequate, well-controlled studies in pregnant women, SUSTIVA should
be used during the first trimester of pregnancy only if the potential benefit justifies the
potential risk to the fetus, such as in pregnant women without other therapeutic options.
Barrier contraception should always be used in combination with other contraceptive methods.

During the development of SUSTIVA, animal studies were performed to assess the potential for birth defects.
Malformations were observed in 3 of 20 fetuses/infants from efavirenz-treated cynomolgus monkeys
(versus 0 of 20 concomitant controls) in a developmental toxicity study. The pregnant monkeys were
dosed throughout pregnancy (postcoital days 20-150) with efavirenz 60 mg/kg daily, a dose resulting
in plasma drug concentrations similar to those in humans given 600 mg/day of SUSTIVA.
Anencephaly and unilateral anophthalmia were observed in one monkey fetus, microophthalmia
was observed in another fetus, and cleft palate was observed in a third fetus. Efavirenz crosses
the placenta in cynomolgus monkeys and produces fetal blood concentrations similar to maternal
blood concentrations. An increase in fetal resorptions was observed in rats given efavirenz doses
that produced peak plasma concentrations and area under the curve (AUC) values in female rats
equivalent to or lower than those achieved in humans given 600 mg once daily of SUSTIVA.
Efavirenz produced no reproductive toxicities when given to pregnant rabbits at doses that
produced peak plasma concentrations similar to and AUC values approximately half of those
achieved in humans given 600 mg once daily of SUSTIVA.

Limited data are available regarding birth defects occurring after intrauterine exposure to SUSTIVA.
The outcomes of pregnancy have been reviewed for 206 women (207 fetuses) after being exposed
to efavirenz-containing regimens, most of which were first-trimester exposures. Birth defects occurred
in 5 of 188 live births with first-trimester exposure and in 0 of 13 live births with second- or third-trimester
exposure. None of these prospectively reported defects were neural tube defects. However, there have
been 4 retrospective reports (i.e., after the results of the pregnancy were known) of findings consistent
with neural tube defects, including 3 cases of meningomyelocele. All 4 mothers were exposed to
efavirenz-containing regimens in the first trimester. Although a causal relationship of these events
to the use of SUSTIVA has not been established, similar defects have been observed in
preclinical studies of efavirenz.

Antiretroviral Pregnancy Registry: To monitor fetal outcomes of pregnant women exposed to SUSTIVA,
an Antiretroviral Pregnancy Registry has been established.
Physicians are encouraged to register patients by calling (800) 258-4263.

Please refer to the accompanying Important Information about SUSTIVA and the enclosed SUSTIVA Full
Prescribing Information.

If you have any questions about this new information or require additional medical information, please contact
the Virology Medical Services Department at Bristol-Myers Squibb Company at
1-800-426-7644 (select Option 3).

Sincerely,

Freda C. Lewis-Hall, MD
Senior Vice President, Medical Affairs
Bristol-Myers Squibb Company

SUSTIVA is a registered trademark of Bristol-Myers Squibb Pharma Company.

Enclosure: SUSTIVA (efavirenz) Package Insert

REFERENCE
1. SUSTIVA Package Insert, Bristol-Myers Squibb Co., Princeton, New Jersey.

Important Information About SUSTIVA (efavirenz) Capsules and Tablets

INDICATION:

SUSTIVA (efavirenz) in combination with other antiretroviral agents is indicated for the treatment of HIV-1
infection. This indication is based on two clinical trials of at least one year duration that
demonstrated prolonged suppression of HIV RNA.

IMPORTANT SAFETY INFORMATION:

?? Coadministration with astemizole, cisapride, midazolam, triazolam, ergot derivatives, or voriconazole
is contraindicated. Concomitant use of SUSTIVA and St. John’s wort (Hypericum perforatum) or
St. John’s wort-containing products is not recommended. This list of medications is not complete.
?? Serious psychiatric adverse experiences, including severe depression (2.4%), have been reported
in patients treated with SUSTIVA. In addition to SUSTIVA, factors identified in a clinical study that
were associated with an increase in psychiatric symptoms included history of injection drug use,
psychiatric history, and use of psychiatric medication. There have been occasional reports of suicide,
delusions, and psychosis-like behavior, but it could not be determined if SUSTIVA was the cause.
Patients with serious psychiatric adverse experiences should be evaluated immediately to determine
whether the risks of continued therapy outweigh the benefits.
?? Fifty-three percent of patients reported nervous system symptoms when taking SUSTIVA
compared to 25% of patients receiving control regimens. These symptoms usually begin during
Days 1-2 of therapy and generally resolve after the first 2-4 weeks of therapy. Nervous system
symptoms are not predictive of less frequent serious psychiatric symptoms.
?? SUSTIVA may cause fetal harm when administered to a pregnant woman. Women should
not become pregnant or breastfeed while taking SUSTIVA. Barrier contraception must always be
used in combination with other methods of contraception (e.g., oral or other hormonal contraceptives).
If a woman becomes pregnant while taking SUSTIVA during the first trimester of pregnancy, she
should be apprised of the potential harm to the fetus.
?? Mild to moderate rash is a common side effect of SUSTIVA. In controlled clinical trials, 26% of
patients treated with SUSTIVA experienced new-onset skin rash compared with 17% of patients
treated in control groups. SUSTIVA should be discontinued in patients developing severe rash
associated with blistering, desquamation, mucosal involvement, or fever. Rash is more common
and often more severe in pediatric patients.
?? Liver enzymes should be monitored in patients with known or suspected hepatitis B or C
and when SUSTIVA is administered with ritonavir.
?? Use SUSTIVA with caution in patients with a history of seizures.
?? Redistribution and/or accumulation of body fat have been seen in patients receiving antiretroviral
therapy. A causal relationship has not been established.
?? Immune reconstitution syndrome has been reported in patients treated with combination
antiretroviral therapy, including SUSTIVA.
?? It is recommended that SUSTIVA be taken on an empty stomach, preferably at bedtime. The
increased concentrations following administration of SUSTIVA with food may lead to an increase in
frequency of adverse events. Dosing at bedtime may improve the tolerability of nervous system symptoms.

Richard Klein
Office of Special Health Issues
Food and Drug Administration

Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration

An archive of past list serve announcements is available on the FDA web site
at http://www.fda.gov/oashi/aids/listserve/archive.html

U. S. Food and Drug Administration
5600 Fishers Lane, Rockville MD 20857-0001
1-888-INFO-FDA (1-888-463-6332)